ARS Pharma files merger financials: 2021 revenue $5.5M, net loss $20.2M

ARS Pharmaceuticals, Inc.

Audited 2021 revenue $5.5M vs $17.8M in 2020; net loss $20.2M vs $1.1M.
Cash $60.1M at Dec 31, 2021; accumulated deficit $42.3M; expects continued losses.
Product candidate ARS-1 (Neffy) for needle-free epinephrine in anaphylaxis.
Merger with Silverback closed Nov 2022; this amendment provides previously missing financials.
Pro forma combined financials filed as Exhibit 99.3; shows combined entity post-merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.